Beyond Air (NASDAQ:XAIR) (NASDAQ: XAIR) is a clinical-stage medical device company focused on the development and commercialization of proprietary, gas-enabled therapeutics for hospital and outpatient settings. The company’s core technology delivers inhaled nitric oxide (iNO) on demand to target and treat diseases of the respiratory tract, leveraging the antimicrobial, anti-inflammatory and vasodilatory properties of gas-formulated nitric oxide. Beyond Air is advancing these therapies to address serious pulmonary conditions with significant unmet medical need.
The company’s lead platform, LungFit™ PH, is designed to provide optimized gas delivery for patients with pulmonary hypertension and other vascular lung disorders. LungFit devices generate and dispense pure nitric oxide at precise concentrations, enabling continuous outpatient treatment without reliance on compressed gas cylinders. Beyond Air is also pursuing applications of iNO in bronchiectasis, cystic fibrosis and in clearing drug-resistant pulmonary infections. Ongoing clinical trials and regulatory submissions aim to expand approved indications in the United States and Europe.
Founded in 2004 and headquartered in Brooklyn, New York, Beyond Air has its U.S. manufacturing and research operations in Massachusetts. The company’s management has steered a series of strategic partnerships and academic collaborations to advance clinical programs, including work with major medical centers in North America and the European Union. Beyond Air completed its initial public offering in 2021, positioning the organization to accelerate commercialization efforts and scale its product pipeline.
Under the leadership of Chief Executive Officer Eric A. Dyer, Beyond Air’s executive team combines expertise in medical devices, pharmaceutical development and regulatory affairs. The company remains committed to expanding access to inhaled nitric oxide therapy through ongoing research, manufacturing scale-up and health-economic studies. Beyond Air continues to explore new indications and delivery platforms to broaden the impact of its proprietary gas technology on respiratory health worldwide.
